Bitdeer Reports Financial Results for the Full Year 2023 and Operational Update
SINGAPORE, March 29, 2024 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company […]
TMT Acquisition Corp Announces Adjournment of Extraordinary General Meeting
New York, New York, March 28, 2024 (GLOBE NEWSWIRE) — TMT Acquisition Corp (Nasdaq: TMTCU, TMTC, and TMTCR) (the “Company”) […]
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 […]
TSX News -
Probe Gold Appoints Shannon McCrae to its Board of Directors
TORONTO, March 28, 2024 (GLOBE NEWSWIRE) — PROBE GOLD INC. (TSX: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is very pleased […]
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline […]
Puma Exploration Closes $625,000 Charity Flow-Through Private Placement
RIMOUSKI, Québec, March 28, 2024 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSX-V: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) announces […]
Shapeways Reports Fourth Quarter and Full Year 2023 Results
– Expands Q4 2023 Gross Margins to 46% and Increases Gross Profit by 23% vs the same quarter in the […]
Par Pacific Announces Expected Term Loan Repricing
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific”) today announced it expects to […]
Maui Land & Pineapple Company Reports Fiscal 2023 Results
KAPALUA, Hawaii, March 28, 2024 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results […]
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim […]
